Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD. METHODS: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13-25), were aged 50-90 years, and were taking donepezil 10 mg daily for > or 3 months prior to screening. Entry low-density lipoprotein cholesterol levels (LDL-C) were > 95 and < 195 mg/dL. Patients were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global function (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 weeks. RESULTS: A total of 640 patients were randomized in the study. There were no significant differences in the coprimary endpoints of ADAS-cog or ADCS-CGIC or the secondary endpoints. Atorvastatin was generally well-tolerated. CONCLUSIONS: In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. This treatment was generally well-tolerated without unexpected adverse events. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that intensive lipid lowering with atorvastatin 80 mg/day in patients with mild to moderate probable Alzheimer disease (aged 50-90), taking donepezil, with low-density lipoprotein cholesterol levels between 95 and 195 mg/dL over 72 weeks does not benefit cognition (as measured by Alzheimer's Disease Assessment Scale-Cognitive Subscale) (p = 0.26) or global function (as measured by Alzheimer's Disease Cooperative Study Clinical Global Impression of Change) (p = 0.73) compared with placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies have suggested a beneficial effect of aspirin on cognition,465,466 although this was not confirmed in others.467,468”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
A nonparametric method for automatic correction of intensity nonuniformity in MRI data
Sled, J. G., Zijdenbos, A. P., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.668698 · Cited by 4,731
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Research works printed but not linked: 3
- Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:63–70.
- Austen B, Frears E, Davies H. Cholesterol upregulates production of A[beta] 1-40 and 1-42 in transfected cells. Neurobiol Aging 2000;21:254.
- Hoglund K, Wallin A, Blennow K. Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:87–92.
Cited by
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Self-citationMicroglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Alzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 937
Linking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972
“, but clinical trials and prospective cohort studies have produced inconsistent, mixed result”
ResultGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 907
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801
Statin Toxicity: Mechanistic Insights and Clinical Implications
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 757
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Statin-Associated Side Effects
Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 739
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Self-citationMendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality
Evans, D. M., & Davey Smith, G. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-050016 · Cited by 528
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
Review: Systemic inflammation andAlzheimer's disease
Holmes, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01307.x · Cited by 356
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bf11 · Cited by 336
Abraldes, J. G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., Rodriguez, M., Castellote, J., García-Pagán, J. C., Torres, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.004 · Cited by 339
Cholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
Vascular Cognitive Impairment (VCI)
Rundek, T., Tolea, M., Ariko, T., Fagerli, E. A., & Camargo, C. J. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01170-y · Cited by 305
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Pearn, M. L., Niesman, I. R., Egawa, J., Sawada, A., Almenar-Queralt, A., Shah, S. B., Duckworth, J. L., & Head, B. P. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0400-1 · Cited by 296
“Case studies have shown that statins result in attention deficits, decreased psychomotor speed, reduced neuropsychological performance, and memory loss (Wagstaff et al. 2003; Muldoon et al. 2004; Evans and Golomb 2009; Feldman et al. 2010; Maningat et al. 2011; Padala et al. 2012).”
BackgroundTau-aggregation inhibitor therapy for Alzheimer's disease
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 262
Targeting neuroinflammation in Alzheimer’s disease
Bronzuoli, M. R., Iacomino, A., Steardo, L., & Scuderi, C. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s86958 · Cited by 255
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258
Sierra, S., Ramos, M. C., Molina, P., Esteo, C., Vázquez, J. A., & Burgos, J. S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101179 · Cited by 248
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Current and Emerging Drug Treatment Options for Alzheimerʼs Disease: A Systematic Review
Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 237
Targeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E. W. G. M., Boza-Serrano, A., Brioschi, S., Castro-Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 233
Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ott, B. R., Daiello, L. A., Dahabreh, I. J., Springate, B. A., Bixby, K., Murali, M., & Trikalinos, T. A. (2015) · Journal of General Internal Medicine · doi:10.1007/s11606-014-3115-3 · Cited by 239
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 230
Statins for the treatment of dementia
McGuinness, B., Craig, D., Bullock, R., Malouf, R., & Passmore, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub3 · Cited by 216
Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Jiang, T., Yu, J.-T., Tian, Y., & Tan, L. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990155 · Cited by 225
Docosahexaenoic Acid Reduces Amyloid β Production via Multiple Pleiotropic Mechanisms
Grimm, M. O. W., Kuchenbecker, J., Grösgen, S., Burg, V. K., Hundsdörfer, B., Rothhaar, T. L., Friess, P., de Wilde, M. C., Broersen, L. M., Penke, B., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.182329 · Cited by 220
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Mayeux, R. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0910236 · Cited by 206
Grill, J. D., & Karlawish, J. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt58 · Cited by 198
Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets
Dai, L., Zou, L., Meng, L., Qiang, G., Yan, M., & Zhang, Z. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02232-6 · Cited by 194
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
Geifman, N., Brinton, R. D., Kennedy, R. E., Schneider, L. S., & Butte, A. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0237-y · Cited by 191
Dyslipidemia and the Risk of Alzheimer’s Disease
Reitz, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0307-3 · Cited by 190
Shepardson, N. E. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.242 · Cited by 181
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Williams, T., Borchelt, D. R., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 171
Is Alzheimer’s Disease Risk Modifiable?
Serrano-Pozo, A., & Growdon, J. H. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad181028 · Cited by 154
“After 72 weeks, no differences were observed in the primary endpoints: a measure of global cognition and a measure of global level of functioning [119].”
Hu, X., Pickering, E., Liu, Y. C., Hall, S., Fournier, H., Katz, E., Dechairo, B., John, S., Van Eerdewegh, P., Soares, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016616 · Cited by 159
APOE and cholesterol homeostasis in Alzheimer's disease
Leduc, V., Jasmin-Bélanger, S., & Poirier, J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.008 · Cited by 160
Rahimi, K., Emberson, J., McGale, P., Majoni, W., Merhi, A., Asselbergs, F. W., Krane, V., Macfarlane, P. W., & Executive, P. I. A. O. B. O. T. P. (2011) · BMJ · doi:10.1136/bmj.d1250 · Cited by 159
Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance
Ezkurdia, A., Ramírez, M. J., & Solas, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054354 · Cited by 169
Risk of Alzheimer’s Disease in Relation to Diabetes: A Population-Based Cohort Study
Wang, K.-C., Woung, L.-C., Tsai, M.-T., Liu, C.-C., Su, Y.-H., & Li, C.-Y. (2012) · Neuroepidemiology · doi:10.1159/000337428 · Cited by 148
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis
Tonelli, M., Lloyd, A., Clement, F., Conly, J., Husereau, D., Hemmelgarn, B., Klarenbach, S., McAlister, F. A., Wiebe, N., Manns, B., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.101280 · Cited by 150
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Sagare, A. P., Deane, R., & Zlokovic, B. V. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.008 · Cited by 143
Cirrhosis as new indication for statins
Bosch, J., Gracia-Sancho, J., & Abraldes, J. G. (2020) · Gut · doi:10.1136/gutjnl-2019-318237 · Cited by 141
Statins and Inflammation: New Therapeutic Opportunities in Psychiatry
Kim, S.-W., Kang, H.-J., Jhon, M., Kim, J.-W., Lee, J.-Y., Walker, A. J., Agustini, B., Kim, J.-M., & Berk, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00103 · Cited by 136
Role of natural products for the treatment of Alzheimer’s disease
Noori, T., Dehpour, A. R., Sureda, A., Sobarzo-Sanchez, E., & Shirooie, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173974 · Cited by 141
Midlife Vascular Risk Factors and Alzheimer's Disease: Evidence from Epidemiological Studies
Tolppanen, A.-M., Solomon, A., Soininen, H., & Kivipelto, M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120802 · Cited by 136
Self-citationAwasthi, M., Singh, S., Pandey, V. P., & Dwivedi, U. N. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.008 · Cited by 148
Bettermann, K., Arnold, A. M., Williamson, J., Rapp, S., Sink, K., Toole, J. F., Carlson, M. C., Yasar, S., DeKosky, S., & Burke, G. L. (2012) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2010.11.002 · Cited by 132
“Prospective clinical trials did not show a protective effect of statins on cognition, but these studies were either not primarily designed to examine the effects of statin on cognitive function and enrolled predominantly participants with advanced vascular disease, including cerebrovascular disease,(19,20) or studied…”
ResultAnimal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 124
“[117] reported in a large-scale randomized controlled trial of 640 mild to moderate AD patients, that atorvastatin was not associated with a significant clinical benefit over 72 weeks.”
BackgroundHypercholesterolaemia and vascular dementia
Appleton, J. P., Scutt, P., Sprigg, N., & Bath, P. M. (2017) · Clinical Science · doi:10.1042/cs20160382 · Cited by 126
Disease-modifying treatments for Alzheimer’s disease
Galimberti, D., & Scarpini, E. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611404470 · Cited by 130
Cholesterol and Late-Life Cognitive Decline
van Vliet, P. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111028 · Cited by 126
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
“…prednisone (Aisen et al. 2000), hydroxychloroquine (Van Gool et al. 2001), simvastatin (Simons et al. 2002) atorvastatin (Sparks et al. 2005; Feldman et al. 2010), aspirin (Bentham et al. 2008) and rosiglitazone (Harrington et al. 2011) have also shown no clinically significant changes in…”
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)
Committee for the Korean Guidelines for the Management of Dyslipidemia (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.3.275 · Cited by 132
Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease
Uddin, M. S., Kabir, M. T., Mamun, A. A., Barreto, G. E., Rashid, M., Perveen, A., & Ashraf, G. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106479 · Cited by 114
Huang, W., Li, Z., Zhao, L., & Zhao, W. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.060 · Cited by 118
Grimm, M. O. W., Michaelson, D. M., & Hartmann, T. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076331 · Cited by 109
The effects of cholesterol on learning and memory
Schreurs, B. G. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.04.010 · Cited by 105
“Nevertheless, in the most recent international, multicenter, double-blind, randomized, parallel-group study with 640 patients, Feldman and associates reported no clinical benefit of atorvastatin as a treatment for mild or moderate Alzheimer’s disease (Feldman et al., 2010).”
BackgroundCavedo, E., Grothe, M. J., Colliot, O., Lista, S., Chupin, M., Dormont, D., Houot, M., Lehéricy, S., Teipel, S., Dubois, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09780-3 · Cited by 109
Resveratrol ameliorates spatial learning memory impairment induced by Aβ 1–42 in rats
Wang, R., Zhang, Y., Li, J., & Zhang, C. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.08.051 · Cited by 118
“Although a number of therapeutic interventions, including vitamin E (Farina et al., 2012; Dysken et al., 2014), statins (Feldman et al., 2010; Sano et al., 2011) and omega-3 fatty acids (Chew et al., 2015), have been applied, none proved effective when tested in the clinic.”
Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty
Kimmelman, J., & London, A. J. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001010 · Cited by 111
APP Function and Lipids: A Bidirectional Link
Grimm, M. O. W., Mett, J., Grimm, H. S., & Hartmann, T. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00063 · Cited by 104
Muszyński, P., Groblewska, M., Kulczyńska-Przybik, A., Kułakowska, A., & Mroczko, B. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170208124324 · Cited by 99
Nampoothiri, M., John, J., Kumar, N., Mudgal, J., Nampurath, G. K., & Chamallamudi, M. R. (2015) · Behavioural Neurology · doi:10.1155/2015/210169 · Cited by 113
Willey, J. Z., & Elkind, M. S. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.199 · Cited by 102
“The Lipitor’s Effect in Alzheimer Dementia study enrolled 640 subjects already taking donepezil hydrochloride (10 mg) and randomized subjects in a doubleblind fashion to receive atorvastatin (80 mg) vs placebo with a baseline LDL-C of 95 to 195 mg/dL.(45) The investigators failed to find a benefit in cognition (as mea…”
MethodIbrahim, S. J. A., & Thangamani, M. (2019) · Measurement · doi:10.1016/j.measurement.2019.02.056 · Cited by 103
The Treatment of Alzheimer Disease
Winslow, B. T., Onysko, M. K., Stob, C. M., & Hazlewood, K. A. (2008) · Springer eBooks · doi:10.1007/978-3-540-87523-9_6 · Cited by 101
Goldstein, L. B., Toth, P. P., Dearborn-Tomazos, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., Woo, D., & on behalf of the American Heart Association Council on Arteriosclerosis, T. A. V. B. C. O. C. A. S. N. C. O. P. V. D. A. S. C. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 92
Rahimi, K., Bhala, N., Kamphuisen, P., Emberson, J., Biere-Rafi, S., Krane, V., Robertson, M., Wikstrand, J., & McMurray, J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001310 · Cited by 94
Animal models of Alzheimer's disease and drug development
Laurijssens, B. E., Aujard, F., & Rahman, A. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.04.001 · Cited by 109
Proitsi, P., Lupton, M. K., Velayudhan, L., Newhouse, S., Fogh, I., Tsolaki, M., Daniilidou, M., Pritchard, M., Kloszewska, I., Soininen, H., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001713 · Cited by 91
Vascular risk factors and Alzheimer’s disease
O’Brien, J. T., & Markus, H. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0218-y · Cited by 93
Frisoni, G. B., & Jack, C. R. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.06.007 · Cited by 99
Lin, F.-C., Chuang, Y.-S., Hsieh, H.-M., Lee, T.-C., Chiu, K.-F., Liu, C.-K., & Wu, M.-T. (2015) · Medicine · doi:10.1097/md.0000000000002143 · Cited by 90
Fernández-Pérez, E. J., Sepúlveda, F. J., Peters, C., Bascuñán, D., Riffo-Lepe, N. O., González-Sanmiguel, J., Sánchez, S. A., Peoples, R. W., Vicente, B., & Aguayo, L. G. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00226 · Cited by 89
“Unfortunately, the most recent large-scale, randomized double-blind placebocontrolled clinical trials with atorvastatin (Feldman et al., 2010) and simvastatin (Mintun et al.”
BackgroundBidirectional links between Alzheimer's disease and Niemann–Pick type C disease
Malnar, M., Hecimovic, S., Mattsson, N., & Zetterberg, H. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.033 · Cited by 89
“While statins do not delay cognitive decline in patients with manifest AD (Feldman et al., 2010; Sano et al., 2011), their role in neuroprotection and the prevention of AD, supported by epidemiologic data (Jick et al., 2000; Wolozin et al., 2000), is still actively being investigated.”
Statins for the treatment of dementia
McGuinness, B., O'Hare, J., Craig, D., Bullock, R., Malouf, R., & Passmore, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub2 · Cited by 92
Role of amyloid beta in lipid homeostasis
Grösgen, S., Grimm, M. O. W., Frieß, P., & Hartmann, T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.002 · Cited by 90
A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
Appleby, B. S., Nacopoulos, D., Milano, N., Zhong, K., & Cummings, J. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345791 · Cited by 90
Metadata
- Authors
- Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., & Breazna, A.
- Affiliations
- San Francisco General Hospital (US)
- From the Division of Neurology (H.H.F.), University of British Columbia, UBCH Clinic for Alzheimer's Disease and Related Disorders, Vancouver, Canada; Department of Neurology (R.S.D.), Baylor College of Medicine, Houston, TX; Aging Research Center (M.K.), Karolinska Institutet, Stockholm, Sweden; Ralph & Muriel Roberts Laboratory For Neurodegenerative Research (D.L.S.), Sun Health Research Institute, Sun City, AZ; San Francisco General Hospital (D.D.W.), San Francisco, CA; RICE (The Research...
- Venue
- Neurology
- Published
- 2010-03-23
- Volume
- 74
- Issue
- 12
- Pages
- 956-964
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2030025114
- Cited by
- 438
- References
- 38
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 18 · 2020: 27 · 2019: 42 · 2018: 16 · 2017: 26 · 2016: 34 · 2015: 26 · 2014: 33 · 2013: 28 · 2012: 49
- FWCI
- 32.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Pfizer
- IXICO
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- atorvastatin, Alzheimer's disease, statins, lipid lowering, donepezil, cognitive function, global function, LDL cholesterol, drug safety and efficacy
- MeSH terms
- Atorvastatin, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Heptanoic Acids, Hippocampus, Humans, Cholesterol, LDL, Magnetic Resonance Imaging, Male, Middle Aged, Organ Size, Pyrroles, Cholinergic Antagonists, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.